Type 1 Diabetes Mellitus
Conditions
Brief summary
Primary Objective: \- To assess the safety of SAR341402 and NovoLog® when used in external insulin pumps in terms of the number of patients with infusion set occlusions. Secondary Objectives: * To assess the safety of SAR341402 and NovoLog® when used in external pumps in terms of unexplained hyperglycemia. * To assess the safety of SAR341402 and NovoLog® when used in external pumps in terms of: * Intervals for infusion set changes. * Number of patients with insulin pump for non-delivery alarm. * Patient observation of infusion set occlusion. * Adverse events and serious adverse events. * Number of patients with hypoglycemic events \[according to ADA (American Diabetes Association) Workgroup on hypoglycemia\].
Detailed description
The study duration for each patient will be approximately 10 weeks, including a 2-week screening period, 2 treatment periods of 4 weeks each, and 1-day post-treatment safety follow-up period.
Interventions
Pharmaceutical form: Solution Route of administration: Subcutaneous
DRUGInsulin aspart
Pharmaceutical form: Solution Route of administration: Subcutaneous
Sponsors
Sanofi
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Male and female patients with Type 1 diabetes mellitus (T1DM). * Age greater than or equal to 18 at the screening visit. * Diabetes diagnosed at least 12 months before screening visit. * At least 1 year of insulin treatment with at least 6 months of CSII (Continuous Subcutaneous Insulin Infusion) treatment with an external insulin pump. * Demonstration of successful use of insulin pump and performing of a minimum of 4 blood glucose checks per day during screening. * Laboratory parameters within the normal range (or defined screening threshold for the Investigator site), unless the Investigator considers an abnormality to be clinically irrelevant for T1DM patients. * Signed written informed consent.
Exclusion criteria
* Hemoglobin A1c (HbA1c) ≥8.5% at screening. * Diabetes other than T1DM. * History of infection at the infusion site within 3 months prior to the screening visit (Visit 1). * Use of oral glucose-lowering agents or any injectable glucose-lowering agents other than insulin during the 3 months before screening visit. * Hospitalization for recurrent diabetic ketoacidosis (DKA) in the last 6 months before screening visit. * History of severe hypoglycemia requiring emergency room admission or hospitalization in the last 6 months before screening visit. * Hypoglycemic unawareness as judged by the Investigator in the last 6 months before the screening visit. * Any clinically significant abnormality identified on physical examination, laboratory tests, or vital signs at the time of screening that in the judgment of the investigator or any sub investigator would preclude safe completion of the study. * Known history of illegal drug or alcohol abuse within 6 months prior to the time of screening. * Use of investigational drug(s) within 3 months or 5 half-lives, whichever is longer, prior to the screening visit. * Patients who had previously received SAR341402 in any other clinical trial. * Any contraindication to the use of NovoLog® as defined in the national product labels; history of hypersensitivity to NovoLog® or to any of the excipients. * Pregnancy and lactation. * If female, pregnancy \[defined as positive β-HCG (Human Chorionic Gonadotropin) in blood or in urine\], breast-feeding. * Patient is an employee or relative of an employee of the sponsor. The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Infusion set occlusions | At week 4 from baseline of each treatment | Number of patients with infusion set occlusions. Infusions set occlusions are defined as infusion set change due to failure to correct hyperglycemia (plasma glucose ≥ 250 mg/dL \[13.9 mmol/L\]) by insulin bolus via the insulin pump. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Unexplained hyperglycemia | At week 4 from baseline of each treatment | Number of patients with unexplained hyperglycemia. Unexplained hyperglycemia is defined as plasma glucose equal or above 250 mg/dL (13.9 mmol/L) whether or not corrected by a bolus through the insulin pump with no apparent material defects, medical, dietary, insulin dosing or pump failure. This will include infusion set occlusion as defined in the primary endpoint. |
| Intervals for infusion set changes | At week 4 from baseline of each treatment | Intervals for infusion set changes will be derived as number of days in the treatment period divided by the number of infusion set changes in the treatment period. |
| Number of patients with insulin pump alarms for non-delivery | At week 4 from baseline of each treatment | Number of patients with insulin pump non-delivery alarms (independent of confirmation of occlusion by hyperglycemia and failure to correct hyperglycemia by insulin bolus via the insulin pump). |
| Patient observation of infusion set occlusion | Up to 10 weeks | Patient observation of infusion set occlusion (independent of confirmation of occlusion by hyperglycemia and failure to correct hyperglycemia by insulin bolus via the insulin pump). |
| Adverse events and serious adverse events | Up to 10 weeks | Number patients with adverse events and/or serious adverse events, including bruising at the infusion site and injection site, and hypersensitivity reactions. |
| Number of patients with hypoglycemic events | At week 4 from baseline of each treatment | Number of patients with hypoglycemic events. |
Countries
United States
Outcome results
None listed